INTRODUCTION
More than 2 billion individuals have been infected with hepatitis B virus (HBV) 68 worldwide. The prophylactic HBV vaccine is a tremendous medical success, which 69 saved countless lives. However, due to its inability to confer therapeutic protection, 70 chronic HBV infections remain a major public health issue affecting approximately 250 71 million individuals (1). Persisting HBV predisposes to end-stage liver diseases, such as 72 liver cirrhosis and hepatocellular carcinoma. According to the WHO, HBV is 73 responsible for more than 850,000 deaths per year (https://www.who.int/news-74 room/fact-sheets/detail/hepatitis-b) (2). Two types of antiviral strategies are currently 75 available for chronic hepatitis B (CHB): PEGylated interferon alpha 2 (PEG-IFNα2) 76 and nucleot(s)ide analogues (NUC), such as Entecavir and Tenofovir. However, both 77 are suboptimal. The treatment with PEG-IFNα2 is associated with significant side 78 effects (e.g., flu-like symptoms, mood disorders, and depression), and long-term virus 79 clearance is limited to approximately one third of treated patients (3). NUC medication 80 selects for viral resistance mutations and is hampered by frequent episodes of 81 rebounding viremia after cessation of antiviral therapy (4). Therefore, alternative 82 strategies for the treatment of chronic HBV infection are urgently needed. 83 The clearance of HBV by the immune system relies on a potent and broad T cell 84 immune response, which usually becomes dysregulated during chronic HBV infection 85 (5) (6) (7) . This exhaustion of HBV-specific T cells is believed to be one major reason for 86 the inability of the host to eliminate the persisting pathogen. Aiming to enhance the 87 patient's own antiviral cellular immune response by therapeutic vaccination, is 88 considered a promising strategy. During the last two decades, countless attempts have 89 been made to establish an effective therapeutic vaccine against CHB (8). For example, 90 existing protein-based prophylactic vaccines have been given to chronically infected 91 patients in order to restore HBV-specific immunity. Unfortunately, it turned out to be 92 unsuccessful (9, 10 ). An antigen-antibody (HBsAg-HBIG) immune complex termed 93 YIC initially showed promising results in preclinical models and in phases IIA and IIB 94 clinical trials (11, 12) . However, the results of a phase III clinical trial enrolling 450 95 patients were disappointing (13) . A number of DNA-based vaccine regimens have 96 shown promising efficacy in pre-clinical animal models, but also failed to generate 97 effective therapeutic responses in humans (8, 14) . Therefore, replicating virus-based 98 vectors, which stimulate a broad range of immune responses including T cell-mediated 99 immunity, gained increasing attention in the field of therapeutic HBV vaccine 100 development. In particular, vectors based on adenoviruses (15) 
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Construction and characterization of a recombinant MCMV expressing the HBV 129 small surface antigen. 130 In order to evaluate the vaccine performance of CMV-based vaccine vectors in small 131 animal models, we inserted an expression cassette comprising the coding sequence of Even if cytomegaloviral vectors may be excellent vectors based on their ability to 204 induce very strong T cell responses against foreign antigens, the use of replication 205 competent HCMV-based vectors in humans is limited by their pathogenicity especially 206 for immunocompromised individuals. One option to circumvent this safety issue is the 207 use of live-attenuated CMV mutants(37), which may be achieved by different means. 208 Therefore, we explored the potential of an HBsAg-expressing MCMV vector, which is 209 replication-competent in cell culture, but highly attenuated in vivo due to the inability 210 to counteract STAT2-dependent IFN signaling resulting from the lack of the gene 211 product pM27 (28, 30, 31) . C57BL/6 mice were inoculated twice with either empty 212 ΔM27-MCMV ('ΔM27-Ctrl') or ΔM27-MCMV expressing HBsAg, for convenience 213 denoted 'ΔM27-HBs' thereafter, and then challenged with an HBV-expressing plasmid 214 through HDI. We also included PBS-treated mice as negative control to evaluate the 215 protective effect of ΔM27-HBs (Fig. 4A ). The clearance of serum HBsAg, HBeAg, and 216 HBV DNA was significantly accelerated in mice vaccinated with ΔM27-HBs as 217 compared to those which received PBS or the empty ΔM27-Ctrl ( Fig. 4B and 4C ). All 218 ΔM27-HBs-vaccinated mice became serum HBsAg negative at 9 dpi, while the PBS-219 treated and ΔM27-Ctrl-infected mice remained 100% positive for serum HBsAg at this 220 time point (Fig. 4B ). Eighty percent of ΔM27-HBs-vaccinated mice also became 221 HBeAg negative and 60% became serum HBV DNA negative at 9 dpi. In contrast, none 222 of the mice from the PBS-treated or ΔM27-Ctrl-infected control groups cleared HBeAg 223 or HBV DNA (Fig. 4C ). The ΔM27-HBs-vaccinated mice were also the only animals 224 that cleared HBsAg and HBcAg from the liver as evident by diminished 225 immunohistochemical staining ( Fig. 4D and 4E ).
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Vaccination with an HBsAg-expressing MCMV attenuated through the deletion 228 of the interferon antagonist pM27 induces potent CD8+ T cell responses. 229 Compared to the PBS-treated control mice, the livers of ΔM27-HBs-vaccinated mice 230 showed significantly higher percentages and absolute numbers of CD8 T cells, but not 231 CD4+ cells (Fig. 5A) . Interestingly, the ΔM27-Ctlr-infected mice also showed a 232 significant increase in both percentages and absolute numbers of CD8+ T cells in the 233 liver as compared to PBS-treated control mice ( Fig. 5A, right intrahepatic anti-HBV CD8+ T cell responses in vivo (data not shown). 251 Significantly higher percentages and absolute numbers of CD8+ T cells in the livers of 252 ΔM27-HBs-vaccinated mice produced IFNγ in response to stimulation with the Env190 253 peptide than stimulated cells from the control groups (Fig. 5F) . Additionally, the 254 absolute numbers of IL-2-producing CD8+ T cells in the liver of ΔM27-HBs-255 vaccinated mice were also significantly increased in response to both Env190 and 256 Core93 peptide stimulations (Fig. 5G) . 257 Taken together, these results demonstrate that an HBsAg vaccination based on an Fig. 6B and 6C ). Eighty percent of MCMV-HBs-vaccinated mice became serum 274 HBsAg negative and 60% became HBV DNA negative at 42 dpi. In contrast, only 20% 275 of the wt-MCMV-infected control mice became serum HBsAg negative and none 276 cleared the HBV DNA viremia (Fig. 6B and 6C) . The MCMV-HBs-vaccinated mice 277 also cleared HBsAg and HBcAg from the liver at 43 dpi, while the wt-MCMV-infected 278 control mice still harbored high levels of HBsAg and HBcAg in the liver (Fig. 6D and 279 6E). 280 Next, we examined the impact of MCMV-HBs vaccination on the intrahepatic anti-281 HBV CTL response. The percentages and absolute numbers of HBsAg-specific CD8 T 282 cells were significantly increased in the liver of MCMV-HBs-vaccinated mice as 283 compared to mice, which received the empty wt-MCMV (Fig. 6F ). Moreover, 284 significantly higher percentages and absolute numbers of liver CD8+ T cells of 285 MCMV-HBs-vaccinated mice were capable of producing IFNγ and TNFα in response 286 to Env190 peptide stimulation than cells derived from control treated mice (Fig. 6G ). 287 The same experimental setup was also applied to explore the therapeutic effect of efficiently in primary hepatocytes in vitro (see e.g., (47)) and the liver in vivo (see e.g., 356 (28)), these results most likely reflect the effector nature of CMV in activating T cells 357 and eliciting robust T cell responses against endogenous antigens. Such MCMV-358 specific T cell responses may explain why MCMV-HBs increases the absolute number 359 of core-specific CD8+ T cells, but not the frequency (Fig. 5E ). In addition, CMV 360 possesses other features favorable for a vaccine vector. Firstly, HCMV can superinfect 361 pre-immune hosts (23, 48). Thus, CMV-based vaccines may be applicable regardless 362 of preexisting immune responses raised by naturally acquired CMVs, which would be 363 favorable due to the high sero-prevalence of HCMV in countries with high incidences 364 of CHB. Secondly, the large genome of CMVs allows CMV to take up large segments 365 of foreign DNA at several different genomic loci. Another advantage might be the 366 prolonged period of productive CMV replication, which can last several month in case 367 of MCMV in mice (49), resulting in continuous antigen expression. The ability of 368 herpesviruses to reactivate locally and spontaneously (50), leading to sequential rounds 369 of immune stimulation, might further enhance potent immunogenicity. 370 Although most primary and recurrent HCMV infections progress subclinically in 371 healthy adults, severe cases do occur (51). Additionally, HCMV causes morbidity and 372 mortality in immune-immature, immune-compromised and immune-senescent 373 individuals. Therefore, it is hard to envisage that authorities such as the FDA would 374 approve vaccines based on virulent HCMVs. Thus, it will be necessary to increase the 375 safety by attenuation. One appealing strategy for the generation of immunogenic and 376 safe vaccines is the use of mutants lacking immune antagonists. Such viruses are by 377 definition attenuated and therefore less likely to cause disease. Due to the inability to 378 counteract a given aspect of immunity, such vectors may even induce superior immune 379 responses. Here, we evaluated the effect of the lack the IFN antagonist pM27. ΔM27-380 MCMV is replication competent in vitro in the absence of IFN treatment but highly 381 attenuated in vivo (28, 30, 31) . Interestingly, the vaccination with the attenuated ΔM27-
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HBs showed superior protection compared to MCMV-HBs in terms of breaking the 383 HBV tolerance in HBV persistent mice. Thus, the residual and temporary replication of 384 the attenuated ΔM27-HBs vaccine generated sufficient numbers of HBsAg-specific 385 CD8+ T cells to protect mice from the HBV challenge. Interferons stimulate the 386 expression of several proteins involved in antigen processing and MHC presentation 387 (see e.g., (52)). In conjunction with TCR activation and co-stimulatory molecules, IFNs 388 can also serve as third signal for T cell activation (53). Thus, it is tempting to speculate 389 that the inability of the MCMV vector to counteract STAT2-dependent IFN signaling 390 is beneficial in terms of raising HBsAg-specific CD8 responses. 398 MCMV vectors were constructed by bacterial artificial chromosome (BAC) technology 399 as described (54, 55) . The coding sequence of the sHBsAg was amplified by PCR using 400 the following primers, which introduce a C-terminal HA tag and harbour flanking 401 restriction sites: MR-NheI-sHBsAg-fw (5'-tat gct agc atg gag aac atc aca tca gga ttc c- 
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